Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
I think we had all been expecting less, given that the launch of Novos previous obesity drug, Saxenda, wasnt very successfulalbeit with about 5% weight loss. However, investors have now definitely taken note, changing the landscape of pharma stocks
GLP-1 infusion results in decrease insulin demands
Less motivated
It may be a better fit for patients interested in tirzepatide but concerned about side effects or rapid escalation
Rhythm Pharmaceuticals response to May 5, 2023 CADTH request for additional information regarding setmelanotide review
US$ 21.37
US$ 21.89
US$ 23.71
US$ 27.41
US$ 25.88
US$ 29.90
US$ 24.62
US$ 29.32
